Oruka Therapeutics Inc (ORKA) Stock Price, Quote & News - Mboum

Company Profile

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. T...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 606 7910

Website: orukatx.com

Address:

855 Oak Grove Avenue, Suite 100, Menlo Park, United States

thesheiktrader Sep. 20 at 11:20 PM

$ORKA looks a leak of good positive results of phase 2, we will have good news soon

1 · Reply

Equibles Sep. 19 at 8:37 PM

$ORKA Found it in the filings on Equibles. Oruka Therapeutics, Inc. director Klein Lawrence Otto reported selling 2,452 ORKA shares on September 15, 2026, worth about $234.7 thousand, in a non-derivative Form 4.

1 · Reply

DanFitz Sep. 1 at 12:17 AM

Shakeout or Breakdown? Let's look at Oruka Therapeutics $ORKA https://youtu.be/u_Xy4st20oM

1 · Reply

1234zerp Aug. 31 at 2:31 PM

$ORKA 107% upside according to tipranks. it's not getting cheaper than this!

0 · Reply

thesheiktrader Aug. 31 at 10:47 AM

$ORKA buyin more now, never will see more cheap

1 · Reply

1234zerp Aug. 27 at 3:50 PM

$ORKA Big dip buying opportunity. Most analyts have this at a target of 180

0 · Reply

focafoca99 Aug. 24 at 8:17 PM

$ORKA hired Todd Edwards as its new chief commercial officer, with a $525K base salary and equity grants.

2 · Reply

thesheiktrader Aug. 20 at 11:45 AM

$WETO $AZI $ORKA today rally

0 · Reply

STRelativeStrength Aug. 19 at 6:35 PM

$ORKA undiscovered breakout with 417 watchers

2 · Reply

Pika_Capital Aug. 18 at 4:31 AM

$MTSR $ORKA $IMVT This is one of the wildest move ive ever made in bios. Proceeds from mtsr (buyout +100% gain) compounded +600% in orka and +200% in imvt. Trying to keep emotions in check though. It's very easy to lose everything in this sector.

2 · Reply

Latest News on ORKA

Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference

Sep 9, 2026, 4:01 PM EDT - 12 days ago

Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference

Oruka Therapeutics appoints Todd Edwards as chief commercial officer

2026-08-24T20:05:07.000Z - 4 weeks ago

Oruka Therapeutics appoints Todd Edwards as chief commercial officer

Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer

Aug 24, 2026, 4:01 PM EDT - 4 weeks ago

Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer

Oruka Therapeutics files $1B mixed securities shelf

2026-08-21T20:25:09.000Z - 4 weeks ago

Oruka Therapeutics files $1B mixed securities shelf

Oruka Therapeutics Registration statement: Registration filing

Aug 21, 2026, 8:00 AM EDT - 4 weeks ago

Oruka Therapeutics Registration statement: Registration filing

Oruka Therapeutics reports Q2 EPS (55c), consensus (50c)

2026-08-10T11:26:27.000Z - 6 weeks ago

Oruka Therapeutics reports Q2 EPS (55c), consensus (50c)

Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 10, 2026, 7:03 AM EDT - 6 weeks ago

Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Oruka Therapeutics Earnings release: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 6 weeks ago

Oruka Therapeutics Earnings release: Q2 2026

Oruka Therapeutics Quarterly report: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 6 weeks ago

Oruka Therapeutics Quarterly report: Q2 2026

Oruka Therapeutics falls -8.1%

2026-07-02T14:05:25.000Z - 2 months ago

Oruka Therapeutics falls -8.1%

Oruka Therapeutics price target raised to $130 from $100 at UBS

2026-07-01T11:10:49.000Z - 2 months ago

Oruka Therapeutics price target raised to $130 from $100 at UBS

Oruka Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 3:45 PM EDT - 3 months ago

Oruka Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Oruka Therapeutics Transcript: AGM 2026

Jun 2, 2026, 11:00 AM EDT - 3 months ago

Oruka Therapeutics Transcript: AGM 2026

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

May 28, 2026, 8:00 AM EDT - 3 months ago

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Oruka Therapeutics reports Q1 EPS (48c), consensus (54c)

2026-05-13T20:31:09.000Z - 4 months ago

Oruka Therapeutics reports Q1 EPS (48c), consensus (54c)

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026, 4:03 PM EDT - 4 months ago

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Oruka Therapeutics Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 4 months ago

Oruka Therapeutics Quarterly report: Q1 2026

Oruka Therapeutics Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 4 months ago

Oruka Therapeutics Earnings release: Q1 2026

Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis

2026-05-07T06:12:19.000Z - 4 months ago

Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

May 6, 2026, 8:00 AM EDT - 4 months ago

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics price target raised to $120 from $109 at Leerink

2026-04-30T10:05:54.000Z - 4 months ago

Oruka Therapeutics price target raised to $120 from $109 at Leerink

Oruka Therapeutics price target raised to $120 from $75 at H.C. Wainwright

2026-04-29T10:23:22.000Z - 4 months ago

Oruka Therapeutics price target raised to $120 from $75 at H.C. Wainwright

Oruka Therapeutics $700M Secondary priced at $72.50

2026-04-28T23:45:20.000Z - 4 months ago

Oruka Therapeutics $700M Secondary priced at $72.50

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Apr 28, 2026, 7:42 PM EDT - 4 months ago

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics price target raised to $100 from $75 at UBS

2026-04-28T12:29:34.000Z - 4 months ago

Oruka Therapeutics price target raised to $100 from $75 at UBS

Oruka Therapeutics announces $500M common stock, warrants offering

2026-04-27T20:30:08.000Z - 4 months ago

Oruka Therapeutics announces $500M common stock, warrants offering

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Apr 27, 2026, 4:17 PM EDT - 4 months ago

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Oruka Therapeutics price target raised to $131 from $71 at Clear Street

2026-04-27T20:15:11.000Z - 4 months ago

Oruka Therapeutics price target raised to $131 from $71 at Clear Street

Oruka Therapeutics rises 19.0%

2026-04-27T16:08:26.000Z - 4 months ago

Oruka Therapeutics rises 19.0%

Oruka Therapeutics price target raised to $160 from $78 at Barclays

2026-04-27T15:46:42.000Z - 4 months ago

Oruka Therapeutics price target raised to $160 from $78 at Barclays

Oruka Therapeutics price target raised to $165 from $85 at Wedbush

2026-04-27T15:46:21.000Z - 4 months ago

Oruka Therapeutics price target raised to $165 from $85 at Wedbush

Oruka Therapeutics price target raised to $200 from $125 at Guggenheim

2026-04-27T15:30:18.000Z - 4 months ago

Oruka Therapeutics price target raised to $200 from $125 at Guggenheim

Oruka Therapeutics rises 23.5%

2026-04-27T14:34:43.000Z - 4 months ago

Oruka Therapeutics rises 23.5%

Oruka Therapeutics Transcript: Status update

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Oruka Therapeutics Transcript: Status update

Oruka Therapeutics Press release: Status update

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Oruka Therapeutics Press release: Status update

Oruka Therapeutics Slides: Status update

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Oruka Therapeutics Slides: Status update

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Apr 27, 2026, 7:00 AM EDT - 4 months ago

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

Apr 26, 2026, 12:00 PM EDT - 4 months ago

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

Oruka Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 5 months ago

Oruka Therapeutics Proxy statement: Proxy filing

Oruka Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 5 months ago

Oruka Therapeutics Proxy statement: Proxy filing

Oruka Therapeutics Registration statement: Registration filing

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Oruka Therapeutics Registration statement: Registration filing

Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 12, 2026, 4:05 PM EDT - 6 months ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 6 months ago

Oruka Therapeutics Earnings release: Q4 2025

Oruka Therapeutics Annual report: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 6 months ago

Oruka Therapeutics Annual report: Q4 2025

Oruka Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 1:00 PM EDT - 6 months ago

Oruka Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Feb 9, 2026, 7:00 AM EST - 7 months ago

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Oruka Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 12:00 PM EST - 8 months ago

Oruka Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

Jan 12, 2026, 7:00 AM EST - 8 months ago

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

Oruka Therapeutics Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 8 months ago

Oruka Therapeutics Slides: Corporate presentation

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:00 AM EST - 8 months ago

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Oruka Therapeutics Announces New Board Member and Board Transition

Dec 11, 2025, 4:01 PM EST - 9 months ago

Oruka Therapeutics Announces New Board Member and Board Transition

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:05 PM EST - 10 months ago

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 10 months ago

Oruka Therapeutics Earnings release: Q3 2025

Oruka Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 4:00 PM EST - 10 months ago

Oruka Therapeutics Quarterly report: Q3 2025

Oruka Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 4:40 PM EST - 10 months ago

Oruka Therapeutics Transcript: Stifel 2025 Healthcare Conference

Oruka Therapeutics to Present at Multiple November Investor Conferences

Oct 29, 2025, 7:00 AM EDT - 10 months ago

Oruka Therapeutics to Present at Multiple November Investor Conferences

Oruka Therapeutics Registration statement: Registration Filing

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Oruka Therapeutics Registration statement: Registration Filing

Oruka Therapeutics Registration statement: Registration Filing

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Oruka Therapeutics Registration statement: Registration Filing

Oruka Therapeutics Registration statement: Registration Filing

Oct 3, 2025, 8:00 AM EDT - 11 months ago

Oruka Therapeutics Registration statement: Registration Filing

Oruka Therapeutics Registration statement: Registration Filing

Oct 3, 2025, 8:00 AM EDT - 11 months ago

Oruka Therapeutics Registration statement: Registration Filing

Oruka Therapeutics Slides: Study Presentation

Sep 18, 2025, 7:15 AM EDT - 1 year ago

Oruka Therapeutics Slides: Study Presentation

Oruka Therapeutics Slides: Corporate Presentation

Sep 18, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics Slides: Corporate Presentation

Oruka Therapeutics Slides: Study Presentation

Sep 18, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics Slides: Study Presentation

Oruka Therapeutics Announces $180 Million Private Placement

Sep 17, 2025, 1:02 AM EDT - 1 year ago

Oruka Therapeutics Announces $180 Million Private Placement

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Sep 17, 2025, 1:00 AM EDT - 1 year ago

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 4:04 PM EDT - 1 year ago

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics Earnings release: Q2 2025

Oruka Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics Quarterly report: Q2 2025

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

Jul 21, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

Jul 1, 2025, 4:01 PM EDT - 1 year ago

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

May 21, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

May 20, 2025, 4:01 PM EDT - 1 year ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:15 PM EDT - 1 year ago

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Oruka Therapeutics Quarterly report: Q1 2025

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Oruka Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Oruka Therapeutics Proxy statement: Proxy Filing

Oruka Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Oruka Therapeutics Proxy statement: Proxy Filing

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 6, 2025, 4:09 PM EST - 1 year ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics Earnings release: Q4 2024

Mar 5, 2025, 6:00 PM EST - 1 year ago

Oruka Therapeutics Earnings release: Q4 2024

Oruka Therapeutics Annual report: Q4 2024

Mar 5, 2025, 6:00 PM EST - 1 year ago

Oruka Therapeutics Annual report: Q4 2024

Oruka Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 10:30 AM EST - 1 year ago

Oruka Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Oruka Therapeutics to Present at Multiple March Investor Conferences

Feb 19, 2025, 7:00 AM EST - 1 year ago

Oruka Therapeutics to Present at Multiple March Investor Conferences

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Dec 19, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Dec 18, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Oruka Therapeutics Registration statement: Registration Filing

Nov 14, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Registration statement: Registration Filing

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:25 PM EST - 1 year ago

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Quarterly report: Q3 2024

Oruka Therapeutics Earnings release: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Earnings release: Q3 2024

Oruka Therapeutics Proxy statement: Proxy Filing

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Oruka Therapeutics Proxy statement: Proxy Filing

Oruka Therapeutics Proxy statement: Proxy Filing

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Oruka Therapeutics Proxy statement: Proxy Filing

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Sep 25, 2024, 7:08 AM EDT - 1 year ago

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Oruka Therapeutics Announces $200 Million Private Placement

Sep 12, 2024, 7:05 AM EDT - 2 years ago

Oruka Therapeutics Announces $200 Million Private Placement

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

Aug 29, 2024, 4:50 PM EDT - 2 years ago

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

Aug 26, 2024, 7:30 PM EDT - 2 years ago

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

Aug 23, 2024, 4:30 PM EDT - 2 years ago

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

Aug 16, 2024, 4:15 PM EDT - 2 years ago

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 4:15 PM EDT - 2 years ago

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

May 10, 2024, 6:34 PM EDT - 2 years ago

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

Apr 25, 2024, 4:15 PM EDT - 2 years ago

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Apr 5, 2024, 1:27 PM EDT - 2 years ago

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Arca Biopharma stock ($ABIO) soars on merger news

Apr 3, 2024, 11:38 AM EDT - 2 years ago

Arca Biopharma stock ($ABIO) soars on merger news

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Apr 3, 2024, 7:30 AM EDT - 2 years ago

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

ARCA biopharma Announces 2023 Financial Results

Feb 1, 2024, 4:35 PM EST - 2 years ago

ARCA biopharma Announces 2023 Financial Results

Oruka Therapeutics Proxy statement: Proxy Filing

Dec 19, 2023, 7:00 AM EST - 2 years ago

Oruka Therapeutics Proxy statement: Proxy Filing

Oruka Therapeutics Proxy statement: Proxy Filing

Dec 19, 2023, 7:00 AM EST - 2 years ago

Oruka Therapeutics Proxy statement: Proxy Filing

ARCA biopharma Announces Third Quarter 2023 Financial Results

Oct 18, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces Third Quarter 2023 Financial Results

ARCA biopharma Announces Second Quarter 2023 Financial Results

Jul 21, 2023, 4:25 PM EDT - 3 years ago

ARCA biopharma Announces Second Quarter 2023 Financial Results

thesheiktrader Sep. 20 at 11:20 PM

$ORKA looks a leak of good positive results of phase 2, we will have good news soon

1 · Reply

Equibles Sep. 19 at 8:37 PM

$ORKA Found it in the filings on Equibles. Oruka Therapeutics, Inc. director Klein Lawrence Otto reported selling 2,452 ORKA shares on September 15, 2026, worth about $234.7 thousand, in a non-derivative Form 4.

1 · Reply

DanFitz Sep. 1 at 12:17 AM

Shakeout or Breakdown? Let's look at Oruka Therapeutics $ORKA https://youtu.be/u_Xy4st20oM

1 · Reply

1234zerp Aug. 31 at 2:31 PM

$ORKA 107% upside according to tipranks. it's not getting cheaper than this!

0 · Reply

thesheiktrader Aug. 31 at 10:47 AM

$ORKA buyin more now, never will see more cheap

1 · Reply

1234zerp Aug. 27 at 3:50 PM

$ORKA Big dip buying opportunity. Most analyts have this at a target of 180

0 · Reply

focafoca99 Aug. 24 at 8:17 PM

$ORKA hired Todd Edwards as its new chief commercial officer, with a $525K base salary and equity grants.

2 · Reply

thesheiktrader Aug. 20 at 11:45 AM

$WETO $AZI $ORKA today rally

0 · Reply

STRelativeStrength Aug. 19 at 6:35 PM

$ORKA undiscovered breakout with 417 watchers

2 · Reply

Pika_Capital Aug. 18 at 4:31 AM

$MTSR $ORKA $IMVT This is one of the wildest move ive ever made in bios. Proceeds from mtsr (buyout +100% gain) compounded +600% in orka and +200% in imvt. Trying to keep emotions in check though. It's very easy to lose everything in this sector.

2 · Reply

Whiskeyunderthebed Aug. 15 at 6:34 PM

$ORKA end of the Quarter roster:

0 · Reply

Whiskeyunderthebed Aug. 13 at 1:23 PM

$ORKA another whale just joined our pod-

0 · Reply

Quantumup Aug. 12 at 3:42 PM

BTIG Sees Positive Readthroughs to $JBIO (Buy-$77), $ORKA (Buy-$151), $SYRE (Buy-$132), CBIO (NR), and DMRA (NR) after ABBV (NR) & APGE (⬇️to Neutral) M&A. *Notes APGE as the First Successful Partnered Exit from Paragon Labs/Fairmount of the Group Mentioned Above. Here's what BTIG said in its note to investors: https://x.com/Quantumup1/status/2087565029822320875?s=20

0 · Reply

FlyingChemist01 Aug. 12 at 1:33 PM

$ORKA I will buy shares when goes down below 20$

3 · Reply

thesheiktrader Aug. 11 at 1:37 PM

$ORKA we have in front of us the future of psoriasis

1 · Reply

Stocktwits Aug. 10 at 5:17 PM

$ORKA Added to watchlist ⌚

0 · Reply

MaverikIT Aug. 10 at 5:08 PM

$ORKA - eyeing 52wk$ @cynicaloptimist @WAJeff @BustaCapital @Jblack500 @howardlindzon @IsabellaDC @No_Face_character

1 · Reply

STRelativeStrength Aug. 10 at 5:06 PM

$ORKA undiscovered breakout with 412 watchers

0 · Reply

Pika_Capital Aug. 10 at 3:27 PM

$ORKA $SYRE they will most likely be gone too for a nice premium after $APGE riding it through

1 · Reply

FlyingChemist01 Aug. 10 at 2:57 PM

$ORKA $MLTX that company lives off hype. Basically an overpriced phase 2 promise with an avg 30% success rate for phase 2 companies. If the mAb with extended life will have serious side effects which are common for mAbs the patient will have to endure a long period of suffering out of those symptoms. That will be no good. It's way to early for supporting such a price action, that is just speculation based on a promise, guaranteed if something goes wrong it will plumb down -90%. Remember: globally phase 2 companies have a 30% success rate.

1 · Reply

StockQB Aug. 10 at 2:53 PM

$ORKA up after disappointing $MLTX PA trial results at 16weeks

0 · Reply

Whiskeyunderthebed Aug. 5 at 1:12 PM

$ORKA institutions just can't get enough of this

0 · Reply